Literature DB >> 11907927

Health status of hormone replacement therapy users and non-users as determined by the SF-36 quality-of-life dimension.

D H Wilson1, A W Taylor, A H MacLennan.   

Abstract

BACKGROUND: The objective of this study was to compare the health status of women who use and do not use hormone replacement therapy (HRT).
METHOD: The 1994 South Australian Health Omnibus Survey (a population health interview survey) was used to administer the short form-36 health survey questionnaire (SF-36) to users and non-users of HRT. A representative sample of 813 women aged 40 years and older were interviewed. The response rate of the survey was 72.4%. Eight health dimensions of the SF-36 were measured: physical functioning, social functioning, role limitations owing to emotional problems, role limitations owing to physical problems, mental health, vitality, pain and general health.
RESULTS: The mean score for all eight health dimensions was in the bottom 50% of the population for HRT users while non-users were in the upper 50%. Users of HRT had significantly poorer scores for physical limitations, body pain, general health, vitality, social functioning and mental health.
CONCLUSION: Women who use HRT are less healthy than non-users when measured by a generic health status measure.

Entities:  

Mesh:

Year:  1998        PMID: 11907927     DOI: 10.3109/13697139809080681

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  1 in total

1.  Clinical profile and quality of life in climacteric women.

Authors:  Cíntia Mikaelle Cunha de Santiago Nogueira; Bárbara Daniely Dos Santos Silva; Hosana Mirelle Goes Silva Costa; Jussara Rodrigues de Alcantara; Fátima Raquel Rosado Morais; Renata Janice Morais Lima Ferreira Barros; Susy Maria Feitosa de Melo Rabelo; Emanuelly Vieira Pereira; José Rodolfo Lopes de Paiva Cavalcanti; Natália Teixeira Fernandes; Ana Virginia de Melo Fialho
Journal:  BMC Nurs       Date:  2022-08-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.